Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Autor: Stephen E Gitelman, Brian N Bundy, Ele Ferrannini, Noha Lim, J Lori Blanchfield, Linda A DiMeglio, Eric I Felner, Jason L Gaglia, Peter A Gottlieb, S Alice Long, Andrea Mari, Raghavendra G Mirmira, Philip Raskin, Srinath Sanda, Eva Tsalikian, John M Wentworth, Steven M Willi, Jeffrey P Krischer, Jeffrey A Bluestone, Mayalin Barr, Jeanne Buchanan, Joanne Cabbage, Peter Coleman, Monica De La Vega, Carmella Evans-Molina, Christine Ferrara, Felicity Healy, Laurie Higgins, Megan Hildinger, Margaret Jenkins, Nora Kayton Bryant, Amanda Kinderman, Nisha Koshy, Brianne Kost, Suzanne Krishfield, Olena Kucheruk, Karen Lindsley, Manasa Mantravadi, Shelley Mesfin, Aaron Michels, Mary Ellen Migre, Pantea Minnock, Elham Mohammed-Nur, Jennifer Nelson, Ashvin Nursing, Ryan O'Donnell, Diana Olivos, Melissa Parker, Leanne Redl, Nicole Reed, Brittany Resnick, Peter Sayre, Elisavet Serti, Emily Sims, Karen Smith, Carol Soppe, Fiona Stuart, Sarah Szubowicz, Michel Tansey, Jennifer Terrell, Sarah Tersey, Christine Torok, Kelly Watson, Rebecca Wesch, Steven Willi, Stephanie Woerner

Publikováno v: Lancet Diabetes Endocrinol

Type 1 diabetes results from autoimmune-mediated destruction of β cells. The tyrosine kinase inhibitor imatinib might affect relevant immunological and metabolic pathways, and preclinical studies show that it reverses and prevents diabetes. Our aim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcc88b8333d4324e0044265eff7356ed
https://pubmed.ncbi.nlm.nih.gov/34214480